

CITATION REPORT

List of articles citing

The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review

DOI: 10.1007/s40258-018-0406-6

Applied Health Economics and Health Policy, 2018, 16, 653-66

Source: <https://exaly.com/paper-pdf/71586883/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
35	Drug prices decrease after patent expiry. <i>PharmacoEconomics & Outcomes News</i> , 2018 , 809, 15-15	0.1	
34	Drug prices and trends before and after requesting compulsory licenses: the Ecuadorian experience. <i>Expert Opinion on Therapeutic Patents</i> , 2019 , 29, 653-662	6.8	1
33	Sustainability of Pork Production with Immunocastration in Europe. <i>Sustainability</i> , 2019 , 11, 3335	3.6	17
32	Comment on: "The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review". <i>Applied Health Economics and Health Policy</i> , 2019 , 17, 255-256	3.4	
31	Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. <i>Aids</i> , 2020 , 34, 2259-2268	3.5	13
30	Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. <i>Gut</i> , 2021 , 70, 2172-2182	19.2	11
29	Financial Performance of SDG Mutual Funds Focused on Biotechnology and Healthcare Sectors. <i>Sustainability</i> , 2020 , 12, 2032	3.6	8
28	The impact of patent expiry on drug prices: insights from the Dutch market. <i>Journal of Market Access & Health Policy</i> , 2020 , 9, 1849984	3.7	1
27	Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility. <i>BMC Health Services Research</i> , 2021 , 21, 126	2.9	
26	Technological Advancements in Monoclonal Antibodies. <i>Scientific World Journal, The</i> , 2021 , 2021, 6663708	0.8	2
25	Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab. <i>Pharmacotherapy</i> , 2021 , 41, 332-341	5.8	2
24	Perspectives on Drug Repurposing. <i>Current Medicinal Chemistry</i> , 2021 , 28, 2085-2099	4.3	8
23	Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis. <i>Clinical Breast Cancer</i> , 2021 ,	3	1
22	Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands. <i>Vaccine</i> , 2021 , 39, 3834-3843	4.1	1
21	Social cost of pending the patent examination in Brazil. <i>International Journal for Innovation Education and Research</i> , 2019 , 7, 282-305	0.1	0
20	As capacidades tecnológicas das grandes empresas farmacêuticas nacionais: o caso do Grupo FarmaBrasil.		1
19	Bolar Exception. 2022 , 135-149		

18	Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications.. <i>Value in Health</i> , 2022 , 25, 59-68	3.3	o
17	Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.. <i>PLoS ONE</i> , 2022 , 17, e0262537	3.7	o
16	Estimating Potential for Drug Budget Reallocation Following Expiration of Exclusivity of Pharmaceutical Products.. <i>Journal of Health Economics and Outcomes Research</i> , 2022 , 9, 20-30	1.6	
15	Effect of Patent Expiry on the Performance of Innovator Multinational Pharmaceutical Companies in a Low Middle Income Country.. <i>Frontiers in Medical Technology</i> , 2022 , 4, 783460	1.9	
14	TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.. <i>Pharmaceutics</i> , 2021 , 14,	6.4	o
13	Evergreened drugs or evergreened profits?. <i>Journal of Evaluation in Clinical Practice</i> , 2022 ,	2.5	
12	Limitations of standard cost-effectiveness methods for health technology assessment of treatments for rare, chronic diseases: a case study of treatment for cystic fibrosis.. <i>Journal of Medical Economics</i> , 2022 , 1-30	2.4	1
11	Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis. <i>Alimentary Pharmacology and Therapeutics</i> ,	6.1	o
10	No two classes of biosimilars: Urgent advice to the US Congress and the FDA. <i>Journal of Clinical Pharmacy and Therapeutics</i> ,	2.2	o
9	The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data. 2022 ,		o
8	Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators. 1-15		
7	Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru..		o
6	Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study. 9,		o
5	Dynamics of price competition in Italian pharmaceutical off-patent market. 9,		o
4	Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?.		o
3	The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. 2023 , 8, 458-492		o
2	Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru. 2023 , 21,		o
1	European Healthcare and Biotechnology-Related Mutual Funds and Sustainable Development During COVID-19. 2023 , 1-30		o

